

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
19 May 2023 (19.05.2023)



(10) International Publication Number
WO 2023/081959 A1

(51) International Patent Classification:

C07K 16/46 (2006.01) C12N 9/48 (2006.01)

C07K 19/00 (2006.01)

LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/AU2022/051287

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(22) International Filing Date:

26 October 2022 (26.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2021903609 11 November 2021 (11.11.2021) AU

2022901632 15 June 2022 (15.06.2022) AU

(71) Applicant: THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD [AU/AU]; 85 Commercial Road, Melbourne, Victoria 3004 (AU).

(72) Inventors: HOGARTH, Phillip Mark; 6 Robertson Street, Williamstown, Victoria 3016 (AU). WINES, Bruce David; 48 Anderson Street, Heidelberg, Victoria 3084 (AU).

(74) Agent: MADDERNS PATENT & TRADE MARK ATTORNEYS; GPO Box 2752, Adelaide, South Australia 5001 (AU).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

(54) Title: IMMUNOTHERAPEUTIC PROTEINS COMPRISING AN FC REGION COMPONENT WITH A MUTATION AT POSITION 429

(57) Abstract: An immunotherapeutic protein and methods of use and production thereof are disclosed, wherein the immunotherapeutic protein comprises one or more immunoglobulin heavy chain polypeptide comprising an Fc region component comprising at least a constant heavy chain domain 3 (CH3) domain (or at least a constant heavy domain 4 (CH4) domain), wherein said one or more polypeptide includes an amino acid substitution at a position corresponding to H429 of the amino acid sequence of human IgG1 heavy chain (Eu numbering) such as H429Y and H429F. The immunotherapeutic protein may be in the form of, for example, an antibody, antibody-like molecule or fusion protein. The amino acid substitution may have the effect of enabling the immunotherapeutic protein to oligomerise (eg into a hexameric form) either in solution or upon binding to a relevant target.



WO 2023/081959 A1